New treatment for brain metastases from melanoma
Immune Therapy for Brain Metastasis
This study is looking at how well a combination of two medications, pembrolizumab and bevacizumab, works for people with melanoma that has spread to the brain, aiming to find better treatment options for those facing this tough situation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11059073 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for patients with melanoma that has spread to the brain. It investigates the effectiveness of combining the PD-1 inhibitor pembrolizumab with bevacizumab in patients with untreated brain metastases. The study aims to understand the molecular and cellular mechanisms of brain metastasis and evaluate the safety and efficacy of this combination therapy. By utilizing advanced pre-clinical models and patient data, the research seeks to enhance treatment outcomes for this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma who have untreated brain metastases.
Not a fit: Patients with brain metastases from other types of cancer or those who have already received treatment for their brain metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with melanoma brain metastases, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results with similar combination therapies in treating melanoma brain metastases, indicating potential for success in this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Jilaveanu, Lucia Beatrice — Yale University
- Study coordinator: Jilaveanu, Lucia Beatrice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.